Edgewise Therapeutics Inc. Common Stock vs Viking Holdings Ltd Ordinary Shares — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.32 (market cap $3.94B), while Viking Holdings Ltd Ordinary Shares trades at $82.22 (market cap $36.70B). The key difference: Viking Holdings Ltd Ordinary Shares is far larger — about 9.3× Edgewise Therapeutics Inc. Common Stock's market cap, and Edgewise Therapeutics Inc. Common Stock is trading nearer its 52-week high, Viking Holdings Ltd Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Viking Holdings Ltd Ordinary Shares for 6 Days on average.
| EWTX | VIK | |
|---|---|---|
Market Cap | $3.94B | $36.70B |
Volume | 810,104 | 2,076,556 |
Sector | Health | Consumer Cyclical |
52-Week High | $48.35 | $108.26 |
52-Week Low | $14.89 | $57.08 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $3.48B | $39.07B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Viking Holdings (VIK) trades at $82.16, up 1.72% on the day, with a bullish technical signal and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue for 2025 reached $6.50 billion, with a net income margin of 19.33%, while analyst consensus is strongly bullish with an 86.66% buy rating and a $107.92 price target. Recent news highlights fleet expansion, a $1 billion share repurchase program, and premium positioning in luxury travel.
VIK presents a compelling growth opportunity driven by strong bookings, expanding fleet, and premium valuations, though risks include execution on capital expenditure and sensitivity to travel disruptions. The stock's current price near key support at $81 suggests potential for upward movement toward resistance levels, supported by positive institutional sentiment and operational cash flow strength.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →Viking operates river, ocean, and expedition cruises. Its itineraries focus on destination-based travel across Europe, the Americas, and other regions.
Read more on VIK →